High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
-
Published:2021-12
Issue:6
Volume:45
Page:100759
-
ISSN:0147-0272
-
Container-title:Current Problems in Cancer
-
language:en
-
Short-container-title:Current Problems in Cancer
Author:
Fallara GiuseppeORCID,
Bandini Marco,
Larcher Alessandro,
Pederzoli FilippoORCID,
Karakiewicz Pierre,
Tian Zhe,
Briganti Alberto,
Necchi Andrea,
Salonia AndreaORCID,
Bertini Roberto,
Montorsi Francesco,
Bex Axel,
Capitanio Umberto
Subject
Cancer Research,Oncology
Reference20 articles.
1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma;Motzer;New Engl J Med,2007
2. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016
3. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma;Motzer;J Clin Oncol,2017
4. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial;Gross-Goupil;Ann Oncol,2018
5. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy;Ravaud;New Engl J Medicine,2016
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献